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Abstract 19 
A rapid decline in the development of new antimicrobial therapeutics has coincided with the 20 
emergence of new and more aggressive multidrug resistant pathogens. Pathogens are protected 21 
from antibiotic activity by their ability to enter an aggregative biofilm state. Therefore, disrupting 22 
this process in pathogens is a key strategy for the development of next generation antimicrobials. 23 
Here we present a suite of compounds, based on the Pseudomonas aeruginosa 2-heptyl-4(1H)-24 
quinolone (HHQ) core quinolone interkingdom signal structure, that exhibit non-cytotoxic anti-25 
biofilm activity towards the fungal pathogen Candida albicans. In addition to providing new 26 
insights into what is a clinically important bacterial-fungal interaction, the capacity to modularize 27 
the functionality of the quinolone signals is an important advance in harnessing the therapeutic 28 
potential of signaling molecules in general. This provides a platform for the development of 29 
potent next generation small molecular therapeutics targeting clinically relevant fungal 30 
pathogens. 31 
 32 
 33 
 34 
 35 
 36 
 37 
 38 
 39 
 40 
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Introduction 41 
With the ever increasing emergence of antibiotic resistant pathogens and the lack of new 42 
antibiotics coming to market, we are entering a ‘post-antibiotic era’ (1-3). This realization has 43 
underpinned a global initiative to identify new and innovative approaches to infection 44 
management. As such, targeting virulence as a potential strategy for developing new anti-45 
microbial drugs has been the focus of several research initiatives (4-11). In principle, suppressing 46 
virulence behavior and locking pathogens in a vegetative non-biofilm forming lifestyle renders 47 
them less infective and more susceptible to conventional antibiotics (4, 12). While some success 48 
has been achieved against bacterial pathogens (6, 10, 13-19), less focus has been placed on 49 
fungal infections which nevertheless continue to cause serious complications and mortality in 50 
patients (8, 20-22). Indeed, despite the medical and economic damage caused by fungal biofilms, 51 
there remains an urgent and largely unmet need for the identification of compounds able to 52 
specifically and selectively target and inhibit this mode of growth in clinically relevant fungal 53 
pathogens (23). 54 
The predominant nosocomial fungal pathogens, which include Candida spp., Aspergillus spp., 55 
and Fusarium spp., are difficult to diagnose and cause high morbidity and mortality, even 56 
following antifungal therapy (21). Candida albicans causes a variety of complications ranging 57 
from mucosal disease to deep seated mycoses, particularly in immunocompromised individuals 58 
(21, 24). Along with other fungal and yeast pathogens, C. albicans are known to form structured 59 
communities known as biofilms on medical devices either pre- or post-implantation leading to 60 
recurring infections and in some cases death (25, 26). Once established in the biofilm phase, C. 61 
albicans presents a significant clinical problem with current treatment options severely limited 62 
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by the intrinsic tolerance of fungal biofilms to antimycotics (20, 27, 28). Recent combination 63 
therapies incorporating antibacterial and antifungal agents have provided some success (29). 64 
However, as with all antibiotic based strategies, reports of resistance continue to emerge (27), 65 
and biofilms themselves are considered a breeding ground for the emergence of antibiotic 66 
resistant strains, effectively hastening the onset of the perfect storm whereby the rapid decline in 67 
new antibiotic production has been met by an equally rapid increase in multidrug resistant 68 
organisms (1). Thus the need to consider new anti-infective strategies that do not target essential 69 
processes in the target organism. While blocking biofilms in these organisms’ remains a major 70 
clinical challenge (26, 30), exploiting our increased understanding of microbial signaling 71 
networks to control virulence and biofilm behavior is one innovative approach with significant 72 
potential. 73 
Many sites of infection are colonized by communities of mixed fungal and bacterial organisms, 74 
and several layers of communication impact significantly on the dynamics and flux of these 75 
populations (31, 32). For example, C. albicans is known to co-exist with Pseudomonas 76 
aeruginosa in the cystic fibrosis (CF) lung, and interkingdom communication between the two 77 
organisms has previously been reported (16, 33). The Pseudomonas Quinolone Signal (PQS), 2-78 
heptyl-3-hydroxy-4-quinolone, and its biological precursor 2-heptyl-4-quinolone (HHQ) are 79 
important virulence factors produced by P. aeruginosa. Structurally, PQS and HHQ differ by the 80 
presence of a hydrogen at C3 in HHQ and a hydroxyl group in PQS, giving rise to the increased 81 
interest in modulating this position to assign biological function to the structure of these 82 
molecules (34-37). Previously, we have shown that HHQ, but not PQS, suppresses biofilm 83 
formation of C. albicans (10). In response, C. albicans produces farnesol which has been shown 84 
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to modulate PQS production in P. aeruginosa (33). As both PQS and HHQ promote virulence 85 
and pathogenicity of P. aeruginosa (38, 39), their utility as an anti-Candida treatment falls short 86 
of being a viable anti-fungal treatment. However, the amenability of these small molecules to 87 
chemical modification provides an opportunity to develop compounds with specificity of 88 
function. 89 
The transcriptional data and microscopic imaging described in this study have implicated 90 
components of the cell wall as key factors in the response of C. albicans to P. aeruginosa 91 
alkylhydroxyquinolone (AHQ) signaling. Furthermore, the biological activity of each class of 92 
analogue in bacterial, fungal and host systems provides a new insight into the possible 93 
interkingdom role of AHQs, particularly in a clinical setting such as the CF lung where all three 94 
systems co-exist. From a translational perspective, lead HHQ analogues were identified with four 95 
key features: (1) potent anti-biofilm activity towards C. albicans, (2) selective non-cytotoxicity 96 
towards mammalian cell lines, (3) non-agonistic and (4) potentially antagonistic to the virulent 97 
pathogen P. aeruginosa. Several analogues retained the significant potency of the parent HHQ 98 
molecule against C. albicans biofilm formation, whilst simultaneously becoming inactive in P. 99 
aeruginosa quorum sensing. This suggests that these molecules have the potential to be further 100 
optimized for use as anti-Candida infectives without the concomitant limitation of P. aeruginosa 101 
virulence augmentation. 102 
 103 
Materials and Methods 104 
C. albicans stock maintenance and culturing conditions.  105 
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C. albicans strain SC5314 was sub-cultured from 15% (v/v) glycerol stocks at -80oC onto Yeast 106 
Peptone Dextrose (YPD) medium [1% (w/v) yeast extract, 2% (w/v) peptone and 2% (w/v) 107 
dextrose] and incubated at 30°C overnight.  108 
P. aeruginosa stock maintenance and culturing conditions.  109 
P. aeruginosa strains, PAO1 and pqsA- mutant, containing the chromosomally inserted pqsA-110 
lacZ promoter fusion on plasmid pUC18-mini-Tn7, were maintained on Luria Bertani (LB) agar 111 
plates, supplemented with carbenicillin (200 µg/ml) and X-gal (40 µg/ml), and incubated at 37°C 112 
overnight. Single colonies were inoculated into LB broth (20 ml), supplemented with 113 
carbenicillin (200 µg/ml), and incubated at 37°C, shaking at 180 rpm overnight. For subsequent 114 
experiments, the OD600nm was recorded and a starting OD600nm of 0.02 was inoculated into fresh 115 
LB broth, supplemented with carbenicillin (200 µg/ml) and incubated at 37°C, shaking at 180 116 
rpm. 117 
Structural modification of HHQ 118 
The synthesis of HHQ, PQS (40, 41) and other HHQ-based analogues (36, 37) was carried out 119 
via previously described methods. Novel compounds and compounds which required modified 120 
syntheses are described vide infra and in the supporting information (Supplemental Data). 121 
Thin Layer Chromatographic (TLC) analysis.  122 
Silica TLC plates, activated by soaking in 5% (w/v) K2HPO4 for 30 min were placed in an oven 123 
at 100oC for 1 hr (42). Analogues (5 µl, 10 mM) were spotted approximately 1 cm from the 124 
bottom. The spots were dried and the plate placed in a mobile phase comprising 95:5 125 
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dichloromethane:methanol. The plate was viewed under UV light when the mobile phase had run 126 
5 cm below the top of the plate.  127 
Biofilm formation, quantification, and visualization.  128 
C. albicans biofilm formation was carried out in 96 well plates, as previously described (43). 129 
Seeding densities for all subsequent experiments (n=3) were OD600nm 0.05. Biofilm formation 130 
was measured as previously described using a semi-quantitative tetrazolium salt, 2,3-bis-(2-131 
methoxy-4-nitro-5-sulfophenyl)-2H tetrazolium-5-carboxanilide inner salt (XTT) reduction assay 132 
(44).  Experiments were repeated at least three times, with at least eight technical replicates. 133 
Visualization of biofilm formation was performed on glass coverslips in 6-well plates using 134 
Confocal Scanning Laser Microscopy (CSLM). All images were captured using the Zeiss HBO-135 
100 microscope illuminating system, processed using the Zen AIM application imaging program 136 
and converted to JPGs using Axiovision 40 Ver. 4.6.3.0. A minimum of three independent 137 
biological repetitions were carried out.  138 
Viable colony biofilm assay 139 
C. albicans biofilms, supplemented with analogues and parent compounds, were grown in 6-well 140 
plates and incubated overnight at 37°C. Briefly, C. albicans Yeast Nitrogen Base (YNB) cultures 141 
were measured at OD600nm, diluted to 0.05 in YNB-NP supplemented with analogues, plated onto 142 
6-well plates and incubated for 1 hr at 37oC. Media was removed, wells were washed twice with 143 
sterile PBS and supplemented with fresh YNB-NP with analogues. Plates were incubated 144 
overnight at 37°C after which media was removed and wells washed with sterile PBS. For serial 145 
dilutions, biofilms were cell-scraped into 1 ml PBS, vortexed, and serially diluted into sterile 146 
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PBS. Serial dilutions were plated (100 µl) onto YPD agar and incubating overnight at 37°C. 147 
Colonies were counted and recorded the next day. 148 
C. albicans growth curves 149 
Overnight C. albicans cultures grown in YNB were diluted to 0.05 in YNB supplemented with 150 
analogues. Cultures (200 µl) were added to each well of a 100 well plate and grown for a 24 hr 151 
period on a Bioscreen C spectrophotometer (Growth Curves USA).   152 
RNA isolation and qRT-PCR transcriptional analysis.  153 
Overnight C. albicans cultures were diluted to 0.05 at OD600nm in either YNB or YNB-NP 154 
(Difco). YNB cultures were supplemented with methanol whereas YNB-NP cultures were 155 
supplemented with either 100 µM HHQ or the methanol volume equivalent. Cultures were 156 
grown at 37ºC with agitation (180 rpm) for 6 hr after which they were centrifuged at 4000 rpm, 157 
supernatants discarded and pellets frozen at -20ºC until processing. RNA was isolated using the 158 
MasterPure Yeast RNA purification kit (Cambio Ltd, Cambridge UK) according to 159 
manufacturer's specifications, and was quantified using a ND-1000 Spectrophotometer 160 
(NanoDrop Technologies, USA). Genomic DNA was enzymatically removed using Turbo DNA-161 
free DNase (Ambion), and samples were confirmed DNA free by PCR. RNA was converted to 162 
cDNA using random primers and AMV reverse transcriptase (Promega) according to 163 
manufacturer's instructions. qRT-PCR was carried out using the Universal ProbeLibrary (UPL) 164 
system (Roche) according to manufacturer's specifications, and samples were normalized to C. 165 
albicans actin transcript expression (ACT1). A full list of primers and UPL probes used in this 166 
study is detailed in Supplemental Table 1. 167 
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Phenazine extraction.  168 
P. aeruginosa strains were cultured as described above for 24 hr, with the addition of analogues 169 
(100 µM), and pyocyanin was extracted as described previously (45). Cultures were centrifuged 170 
at 4000 rpm for 10 minutes and the cell free supernatant (5 ml) removed. Chloroform (3 ml) was 171 
added, and mixed by vortex. After centrifugation at 4000 rpm for 5 min, the lower aqueous phase 172 
was transferred to 0.2 M HCl (2 ml). Samples were mixed by vortex and centrifuged at 4000 rpm 173 
for 5 min to separate the phases. An aliquot of the top phase (1 ml) was removed and 174 
spectrophotometrically analyzed at OD570nm. Phenazine production was calculated using the 175 
following formula: OD570nm x 2 x 17.072 and the units expressed in µg/ml.  176 
Promoter fusion based expression analysis.  177 
Promoter fusion analyses were performed in a 96-well format, with β-galactosidase activity 178 
measured as described previously (46). Briefly, overnight cultures of wild-type PAO1 pqsA-lacZ 179 
(pLP0996) and mutant strain PAO1 pqsA- pqsA-LacZ were diluted to OD600nm=0.02 in LB. 180 
Analogues at 100 µM final concentration were added, mixed, aliquoted into 96 well plates and 181 
incubated overnight at 37ºC with shaking. The next day, OD600nm values were recorded in a plate 182 
reader. Aliquots of cells (0.02 ml) were permeabilized [100 mM dibasic sodium phosphate 183 
(Na2HPO4), 20 mM KCl, 2 mM MgSO4, 0.8 mg/mL CTAB (hexadecyltrimethylammonium 184 
bromide), 0.4 mg/mL sodium deoxycholate, 5.4 μL/mL beta-mercaptoethanol] and added to 185 
substrate solution [60 mM Na2HPO4, 40 mM NaH2PO4, 1 mg/mL o-nitrophenyl-β-D-186 
Galactoside (ONPG), 2.7 μL/mL β-mercaptoethanol]. The kinetics of color development was 187 
monitored and the reactions were stopped using 1M NaCO3. OD420nm were recorded as above. 188 
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Miller units were calculated using the following equation; 1000 x [OD420nm/(OD600nm) x 0.02 ml 189 
x reaction time (min)].   190 
Cytotoxicity Assay.  191 
Lactate dehydrogenase (LDH) release from a panel of mammalian cells was assayed as a 192 
measure of cytotoxicity using an LDH colorimetric kit (Roche) according to manufacturers’ 193 
instructions (36). Briefly, IB3-1 lung epithelial cells, A549 human lung adenocarcinoma 194 
epithelial cells, DU-145 human prostate cancer cells and HeLa cervical cancer cells were seeded 195 
onto 96 well plates and treated with methanol (control) and analogues. Following 16 hr 196 
incubation at 37°C and 5% CO2, supernatants were removed and added to catalyst reaction 197 
mixture in a fresh plate and further incubated at 37°C and 5% CO2 for 30 min to allow for color 198 
development. After this period, the plate was analyzed on an ELISA plate reader at OD490nm. 199 
Cytotoxicity was expressed as a percentage of cells treated with 0.1% (v/v) Triton (100% 200 
cytotoxicity).  201 
Statistical analysis.  202 
All graphs were compiled using GraphPad Prism (version 5.01) unless otherwise stated. All data 203 
were analyzed using built-in GraphPad Prism (version 5.01) functions as speciﬁed. The level of 204 
signiﬁcance was set at p = 0.05 (*) and post-hoc comparisons between groups were performed 205 
using the Bonferroni multiple-comparison test. 206 
 207 
 208 
 209 
 210 
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 211 
Results 212 
 213 
Key modifications of the quinolone framework retain anti-biofilm activity towards C. 214 
albicans 215 
The HHQ molecule has previously been shown to suppress biofilm formation in C. albicans at 216 
concentrations from 10 – 100 µM (2.47 – 24.7 µg/ml) independent of any effects on the growth 217 
of planktonic cells (10). Previous structure function analysis of the activity of the quinolone 218 
framework had implicated the C-3 position as a key component of interspecies anti-biofilm 219 
activity (36). We undertook further modification of the HHQ parent molecule with the aim of 220 
developing viable anti-biofilm compounds to target C. albicans. These compounds were 221 
incorporated into a larger collection of alkylquinolone analogues, systematically modified at 222 
different positions on the molecule and classified on the basis of their substitutions relative to the 223 
parent framework HHQ (Table 1).  224 
The suite of analogues was first tested to establish their potency as anti-biofilm compounds 225 
against C. albicans using an optimized XTT assay, a commonly used quantitative method to 226 
assess Candida biofilm mass and growth (47). As previously described (10), HHQ significantly 227 
suppressed biofilm formation when compared to untreated and methanol treated cells, whereas 228 
PQS appeared to induce biofilm formation (Figure 1). When all analogues were similarly 229 
screened by XTT assay, several had similar anti-biofilm activity to HHQ [1 and 2 (class I; 230 
modified at C-3)], 3, 4, 6, 7, 9 (class II; modified anthranilate ring), and 12 (class III; modified 231 
alkyl chain) (Figure 2a). These analogues were diverse members of classes I, II, and III 232 
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suggesting that several components of the HHQ framework contribute to anti-biofilm activity of 233 
the parent compound. A number of substitutions led to intermediate anti-biofilm activity, 234 
including 5, 8, 10, 11, (class II; modified anthranilate ring) and 15 (class V; modified 235 
anthranilate ring and alkyl chain length), while some analogues had completely lost the ability to 236 
suppress C. albicans biofilm formation e.g. 13 (class IV; modified C-4), and the class V 237 
compounds 14, 16, and 17 (Figure 2a). While modification of the C-3 position to produce PQS 238 
led to loss of anti-biofilm activity (Figure 1), incorporation of an –N-NH2 moiety (2) at the 3-239 
position or substitution of C-3 with NH (1), did not affect the ability to suppress C. albicans 240 
biofilm formation (Figure 2a). Addition of Cl at the C6 and C8 positions of the anthranilate ring 241 
(6 and 7) also did not lead to loss of anti-biofilm activity. In contrast, the introduction of 242 
considerable steric bulk with the addition of an n-hexyl alkyl chain at C6 of the anthranilate ring 243 
(5), or elaboration of the aromatic group as with the naphthyl compound (8), resulted in 244 
compounds with significantly less potent anti-biofilm activity relative to HHQ. These data 245 
suggest an exquisite level of specificity for the interaction between HHQ and the C. albicans 246 
biofilm intracellular machinery. Modification of the C2 alkyl chain from n-heptyl (HHQ) to n-247 
nonyl C9 (12) did not affect anti-biofilm activity, while parallel modification of the anthranilate 248 
ring resulted in a complete loss, as with the Class V compounds 16 or 17. Modifying the C-4 249 
position (C=O to C=S) (13), the quinolone thiol exhibited an increase in XTT activity (P<0.05) 250 
relative to controls (Figure 2a), comparable to the increase observed in the presence of PQS 251 
(Figure 1). Previously, we have shown that HHQ elicits a dose-dependent reduction in C. 252 
albicans biofilm formation (10). In order to determine if this also applied to the analogues that 253 
retain anti-biofilm activity, dose response analysis of selected compounds 1, 2, 4, 6, and 12 254 
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representing classes I, II, and IV, was undertaken. This revealed compound specific responses, 255 
with 10 µM of compounds 2, 4, and 12 being sufficient to elicit a statistically significant 256 
reduction in biofilm formation (Figure 2b). All five compounds reduced biofilm formation when 257 
applied at 50 µM and 100 µM. To further confirm the anti-biofilm activity of the lead 258 
compounds, viable colony counts were performed on selected analogues using the maximum 100 259 
µM compound dose. This confirmed the outputs from the XTT assays; all analogues, along with 260 
HHQ, significantly reduced viable biofilm cells in comparison to the control (Figure S1a). 261 
Importantly, the anti-biofilm activity was found to be independent of planktonic growth, which 262 
was unaffected in the presence of selected compounds (Figure S1b). 263 
 264 
Microscopic staining reveals structural changes in C. albicans biofilms 265 
The formation of biofilms in bacteria, yeast and fungi is a highly ordered process involving 266 
multicellular behavior and has been defined in several stages (22). Confocal microscopy 267 
combined with intracellular staining was used to assess structural integrity and cellular 268 
morphology of C. albicans incubated on coverslips. Biofilms were individually stained with each 269 
of the dyes and multiple fields of view were visualized to accurately represent the effect of the 270 
analogues. The biofilm observed for methanol and untreated controls displayed all the 271 
characteristics of a typical C. albicans biofilm and were classified as wild-type (Figure 1). 272 
Calcofluor, Concanavalin A and FUN-1 staining revealed a uniform distribution of 273 
chitin/cellulose and cell wall mannosyl/glucosyl residues indicative of viable wild-type 274 
morphology (Figure 1). Those analogues identified by XTT assay as causing impaired biofilm 275 
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formation (1, 2, 3, 4, 6, 7, 9, 12, and 15) exhibited markedly disrupted structures when grown on 276 
coverslips and were classified as atypical morphologies (Figure 3). Cells treated with class I 277 
analogues were found to be largely compromised in their biofilm forming capabilities and were 278 
classified as morphologically atypical. Biofilms produced with both 1 and 2 were significantly 279 
distorted, displaying a spindle-like phenotype. Hyphae were short in length, and predominantly 280 
displayed yeast cell types rather than hyphal structures. Other structure disrupting analogues 281 
were from Class II, III and V, suggesting that specific modifications on the anthranilate ring and 282 
alkyl chain variation do not significantly affect the anti-biofilm activity compared to the parent 283 
compound (Figure 3).  284 
Some analogues, including those that exhibited intermediate activity in the XTT assay, did not 285 
alter the biofilm structure, with 5, 11, 13, 14 and 16 all placed into the wild-type morphology 286 
group. Biofilms formed in the presence of 13 showed hyper-production of short hyphae, creating 287 
a dense mycelial network (Figure S2). The remaining analogues from Class II; 8 and 10 (Figure 288 
S1) caused significant biofilm disruption with fragmented hyphae, stunted vegetative growth and 289 
considerably large cell debris fields. Cells incubated with the Class V molecule 17 induced a 290 
severely compromised phenotype (Figure S2) where debris fields comprising yeast cells and 291 
blastospores characterized the structural phenotype. 292 
 293 
Enhanced gene transcript expression of HWP1, ECE1, ALS3, IHD1 and the 294 
uncharacterized open reading frame ORF 19.2457 provides a molecular mechanism for 295 
alkyl quinolone activity towards C. albicans 296 
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In addition to providing new insights into the interkingdom relationship between these important 297 
pathogens, there has recently been a strong emphasis placed on ligand receptor interactions and 298 
the need to provide molecular mechanisms for the action of any potential therapeutic compound 299 
(48). We previously implicated TUP1 in the HHQ-mediated suppression of biofilm formation in 300 
C. albicans suggesting a role for the cell-wall in this interaction (10, 16). More recently, several 301 
reports have shown changes in expression of cell-wall associated genes linked to biofilm 302 
formation in this organism (16, 20, 28, 49-51). These included a cohort of eight genes that are 303 
proposed to constitute the core filamentous response network; namely ALS3, ECE1, HGT2, 304 
HWP1, IHD1, RBT1, DCK1, and the gene of unknown function open reading frame orf19.2457 305 
(51). Therefore, transcript expression of a cohort of genes implicated in cell wall biogenesis, 306 
hyphal development, biofilm formation and other related functions that were previously shown to 307 
be upregulated during the morphological transition from yeast to filamentous growth was 308 
investigated (Table S1) (16, 51). The housekeeping gene ACT1 was chosen for normalization 309 
based on previous biofilm studies (52). We observed that several transcripts were hyper-310 
expressed in a HHQ dependent manner; specifically, HWP1, ECE1, ALS3, IDH1 and the as yet 311 
uncharacterized open reading frame (ORF) 19.2457 (Figure 4). The remaining transcripts 312 
(CPH1, EFB1, ESS1, RBT1, TUP1, BCR1, DCK1, and HGT2) yielded expression patterns 313 
similar to control cells (Figure S3). It was perhaps somewhat surprising that, while treatment of 314 
C. albicans with P. aeruginosa supernatants has previously been shown to downregulate 315 
expression of the RBT1, RBT5 and RBT8 genes (16), expression of RBT1 was unaltered in the 316 
presence of HHQ (Figure S3). Taken together, these data suggest that HHQ induces a specific 317 
subset of cell wall proteins in C. albicans. Further work is needed to identify the upstream 318 
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components of this response, although in silico screening of C. albicans genome sequences has 319 
ruled out the presence of an obvious PQS receptor (unpublished data).   320 
 321 
Lead compounds display reduced cytotoxic activity towards specific mammalian cell lines 322 
Evaluating the cytotoxicity of synthetic compounds is crucial in the context of developing 323 
targeted and highly optimized molecular therapeutics that are benign to human cellular 324 
physiology and ideal for use in a clinical environment. In previous work, we showed that 325 
analogue 1 was significantly less cytotoxic than HHQ, with an 80% reduction in LDH release 326 
relative to the parent compound (36). Therefore, the suite of analogues was tested for in vitro 327 
cytotoxicity towards IB3-1 airway epithelial cells. Class I analogues exhibited reduced 328 
cytotoxicity to IB3-1 cells with 2 displaying approximately 34% toxicity (Figure 5a). Several 329 
class II analogues (4, 6, and 9) exhibited reduced cytotoxicity relative to IB3-1 cells treated with 330 
HHQ, with 7 not reaching statistical significance. The class III analogue 12 was comparable to 331 
HHQ. Of the analogues that did not retain anti-biofilm activity, 5, 8, 10 and 11 exhibited variable 332 
cytotoxicity to IB3-1 cells whereas 13 exhibited considerably reduced cytotoxicity to IB3-1 cells 333 
(Figure S4). Finally, 16 exhibited very low levels of cytotoxicity, while 17 was reduced relative 334 
to HHQ treated cells. Compound 15 was the most toxic killing approximately 91% of all cells 335 
(Figure 5a). 336 
In order to achieve a more comprehensive understanding of the selective toxicity of the lead 337 
compounds, several additional cell lines were tested (Figure 5b). LDH release assays were 338 
performed in A549, DU145, and HeLa cell lines in the presence of 100 µM of the lead 339 
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compounds revealed distinct cytotoxicity profiles, with 1 and 9 consistently proving the least 340 
cytotoxic of the compounds tested. Compounds 4 and 6 exhibited reduced cytotoxicity in DU145 341 
cells (although not statistically significant) but were comparable to HHQ in both the A549 and 342 
HeLa cell lines, while compound 2 exhibited increased cytotoxicity relative to HHQ in DU145 343 
cells (Table 2). These data suggest that cell-specific cytotoxicity analysis will need to be 344 
performed prior to the introduction of these compounds in an applied setting.  345 
 346 
HHQ analogues display a spectrum of agonist activity towards P. aeruginosa virulence. 347 
Taken together, compounds 1, 4, 6, and 9 pass both the first and second criteria described above, 348 
i.e. they retain anti-biofilm activity towards C. albicans while exhibiting reduced selective 349 
cytotoxicity towards specific host cell lines. However, both HHQ and PQS are co-inducers of the 350 
virulence associated LysR-Type Transcriptional Regulator; PqsR (41). The structural moieties 351 
that underpin the interaction between HHQ/PQS and PqsR remain to be fully characterized, 352 
although recent studies have reported diverse classes of PqsR antagonist (53-55), and implicated 353 
the hydrophobic pocket situated within the PqsR protein (56). Therefore, in order to assess 354 
whether the lead compounds could elicit a virulence response from P. aeruginosa, phenazine 355 
production and pqsA promoter activity (57) were monitored in a pqsA mutant where the capacity 356 
to produce native HHQ and PQS had been lost.  357 
Both HHQ and PQS restored phenazine production in the pqsA- strain (Figure 6A). In contrast, 358 
the majority of analogues did not restore phenazine production in this strain, with the notable 359 
exception of compound 9. Several analogues from different classes did partially restore 360 
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phenazine production in the mutant background, including 10, 12, and 17 (Figure 6 and Figure 361 
S5). None of the analogues interfered with phenazine production in the wild-type PAO1 strain, 362 
suggesting that they are ineffective as PQS antagonists (Figure S5).  363 
Similarly, while some degree of PqsR agonist activity was observed in the presence of 364 
compounds 6, 9, 10, 12, 13, and 17, only HHQ and PQS significantly induced promoter activity. 365 
All other analogues did not influence promoter activity in this system (Figure 6B and Figure 366 
S5). Somewhat surprisingly, antagonistic activity towards pqsA promoter activity was not 367 
observed, with almost all analogues failing to significantly suppress pqsA promoter activity in 368 
the wild-type strain (Figure S5). The relative ineffectiveness of these analogues as PQS 369 
antagonists may in part be due to hydroxylation of HHQ analogues (H at C3) to PQS analogues 370 
(OH at C3), thus establishing the non-antagonistic behavior explained by a recent report by Lu 371 
and colleagues, where the action of PqsH rendered anti-PQS compounds ineffective through 372 
bioconversion (55).    373 
 374 
Discussion 375 
Current antimicrobial therapies tend to be non-pathogen-specific and there is evidence to suggest 376 
that the availability of relatively non-toxic broad-spectrum therapies has contributed to the 377 
emergence of resistance among both targeted and non-targeted microbes (58, 59). Consequently, 378 
there is an urgent need to innovate new options for the targeted prevention of microbial infection 379 
while avoiding the inevitable emergence of resistance that is the hallmark of broad spectrum 380 
antibiotic therapies (59, 60). Increasingly, industry, academia and regulatory bodies have become 381 
interested in single-pathogen therapies to treat highly resistant or totally resistant bacterial 382 
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pathogens, rightly viewed as an area of high unmet need (61-63). Exploiting interkingdom 383 
communication networks, and the mode of action of the chemical messages or signals employed 384 
therein, offers us a powerful platform from which to deliver on this. 385 
Previously we had shown that the HHQ interkingdom signal molecule from P. aeruginosa could 386 
suppress biofilm formation in C. albicans at concentrations ranging from 10 - 100 µM (2.47 – 387 
24.7 µg/ml) (10). This suppression occurred independent of any growth limitation in planktonic 388 
cells, and morphogenesis on spider media was also found to be unaffected (10). The design and 389 
subsequent analysis of a suite of analogues based on the core HHQ quinolone framework has led 390 
to the identification of several lead compounds that retain anti-biofilm activity towards C. 391 
albicans but exhibit significantly reduced cytotoxicity towards IB3-1 epithelial cells when 392 
compared with the parent HHQ molecule. The selective cytotoxicity of the lead compounds 393 
together with the dose dependent anti-biofilm effects will be key considerations in determining 394 
the cell line specific therapeutic index of lead analogues as part of the ongoing development of 395 
these compounds. Furthermore, unlike HHQ, these lead compounds are now inactive towards the 396 
P. aeruginosa PqsR quorum sensing system, a critical requirement for their potential future 397 
development as anti-biofilm therapeutics. In addition, the ability to generate hydrochloride salts 398 
of the compounds ((36) and data not shown) suggests that solubility of future therapeutics based 399 
on these scaffolds will not be a bottleneck. Several strategies have been proposed for the 400 
implementation of anti-biofilm compounds as clinical therapeutics to target C. albicans biofilm 401 
infections (64). As the HHQ analogues possess anti-biofilm, but not anti-Candida activity, they 402 
would disrupt the formation of biofilms but not likely remove the planktonic cells that remain at 403 
the site of infection. Therefore, combination with conventional anti-fungal compounds would be 404 
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required for effective clearance. Alternatively, where the potency of the anti-biofilm activity can 405 
be synthetically enhanced through further derivatization, clearance by the immune system might 406 
also be realistic. 407 
The molecular mechanisms through which AHQs and the lead compounds identified in this study 408 
disrupt the formation of biofilms by C. albicans remains to be fully elucidated. Previously we 409 
have shown that HHQ does not affect adhesion, but rather impacts directly on the subsequent 410 
developmental stages in a TUP1-dependent manner (10). In this study we have shown that the 411 
expression of several cell-wall associated genes is increased in response to HHQ during the 412 
switch to hyphal growth. These genes have previously been implicated in the formation of C. 413 
albicans biofilms and have been shown to exhibit increased levels of expression during the 414 
hyphal transition (50, 51, 65). Therefore, anti-biofilm compounds might be expected to suppress 415 
this induction rather than enhance it. However, five of the target genes tested exhibited an 416 
increase in expression relative to control cells under inducing conditions. This may be a 417 
reflection of the previous observation that HHQ interferes with the later stages of biofilm 418 
development (10). Alternatively, this hyper-expression phenotype may affect the capacity of the 419 
cell to engineer a community based biofilm. Future studies will focus on elucidating the 420 
pathways through which C. albicans perceives and responds to challenge with HHQ with the aim 421 
of identifying potential therapeutic targets. 422 
Further work using defined in vivo models of biofilm and infection will be required to progress 423 
the development and evaluation of these small molecules as anti-biofilm compounds. Models are 424 
now available for the investigation of infections involving medical devices such as vascular 425 
catheters, dentures, urinary catheters, and subcutaneous implants, as well as mucosal biofilm 426 
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infections (66). The ongoing development of cell-based or animal models to study in vivo 427 
infections (66-69), whether as single pathogen or co-culture systems (70), has provided a well-428 
equipped tool-kit for the pre-clinical assessment of these AHQ-based compounds.  429 
 430 
Conclusions 431 
In this study, we have functionalized the important microbial signaling molecules HHQ and PQS 432 
in order to exploit their interkingdom role to control biofilm formation in C. albicans. In addition 433 
to deciphering further insights into the molecular mechanism through which these chemical 434 
messages elicit a biofilm suppressive response from C. albicans, the bioactivity of several lead 435 
compounds has provided a viable platform for the development of next generation therapeutics. 436 
Crucially, some of these compounds are non-toxic to mammalian cells and have been rendered 437 
incapable of activating P. aeruginosa virulence systems, thus highlighting their potential utility 438 
as an effective therapy combatting human infection.  439 
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Table 1. Compound Data 643 
Compound Structure Yield 
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a % yields are isolated yields over all steps 645 
b TLC on silica plates with Dichloromethane:MeOH (95:5) mobile phase 646 
c Class I – modified C-3; Class II – modified anthranilate ring; Class III – modified alkyl chain; 647 
Class IV – modified C-4; Class V – modified anthranilate ring and alkyl chain. 648 
* New compounds synthesized in this study 649 
 650 
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Table 2. Selective Toxicity Index of Lead Compounds 662 
Compound Selective Toxicity Index 
 IB3-1 A549 DU145 HeLa 
HHQ ** *** ** **** 
PQS * ** * * 
1 * * * * 
2 ** **** **** **** 
4 * **** ** **** 
6 ** *** * **** 
9 * ** * ** 
12 ** *** ** **** 
 663 
% Toxicity * (0-25), ** (26-50), *** (51-75), **** (76-100) 664 
 665 
 666 
 667 
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Figure Legends 668 
Figure 1. C. albicans biofilms are altered in the presence of HHQ. Filamentous C. albicans 669 
biofilms grown in the presence of PQS and HHQ (100 µM) were assessed structurally by 670 
confocal microscopy and metabolically using the XTT biofilm assay. Data (means ± SEM) are 671 
representative of three independent biological experiments and are presented relative to the 672 
untreated control. Two-tailed paired student’s t-test was performed by comparison of C. albicans 673 
in the presence of HHQ and PQS with C. albicans treated with methanol or ethanol (*, p-value ≤ 674 
0.05).  675 
 676 
Figure 2. Decoration of HHQ exhibits variable biofilm activity against C. albicans. (a) A 677 
panel of HHQ derivatized analogues incubated with filamentous C. albicans and screened for 678 
biofilm formation using the metabolic XTT biofilm assay. Data is presented as OD492nm 679 
spectrophotometric output normalized to the untreated control, and is representative of at least 680 
three independent biological replicates, with error bars representing SEM. (b) Dose-dependent 681 
XTT analysis of selected anti-biofilm compounds applied at 10, 50, and 100 µM. Data is the 682 
average of at least two independent biological replicates, each constituting eight technical 683 
replicates. Statistical analysis of both datasets was performed by one-way ANOVA with 684 
Bonferroni corrective testing, and is presented relative to the MeOH control; * p ≤ 0.05, ** p ≤ 685 
0.01 and *** p ≤ 0.001. 686 
 687 
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Figure 3. Microscopic analysis reveals altered biofilm structures. Analogues that lead to 688 
reduced C. albicans biofilm formation in the XTT assay (1, 2, 3, 4, 6, 7, 9, 12, and 15) exhibit 689 
compromised biofilm structures. Filamentous C. albicans biofilm in the presence of analogues 690 
(100 µM) was stained for chitin and cellulose (calcofluor; blue), lectins which binds to sugars, 691 
glycolipids and glycoproteins (concanavalin A; green) and live-dead cells (FUN-1; red).  692 
 693 
Figure 4. Hyphal pathway genes are hyper-expressed in response to HHQ. Transcript 694 
expression analysis (Real Time RT-PCR) of a panel of biofilm genes was assessed in C. albicans 695 
grown in YNB-NP (filamentous inducing media) in 100 µM HHQ for 6 hours at 37°C. All data 696 
was normalized to a housekeeper gene (ACT1). Error bars represent SD of three independent 697 
biological replicates. Two-tailed paired student’s t-test was performed by comparison of HHQ 698 
treated cells with methanol control in YNB-NP inducing medium (*, p-value ≤ 0.05).  699 
 700 
Figure 5. Cytotoxicity towards specific mammalian cell lines is reduced in lead compounds. 701 
(a) Cytotoxicity, measured as a percentage of total lactate dehydrogenase (LDH) released from 702 
IB3-1 cells treated with 0.1% Triton X-100 (100% cytotoxicity), was significantly reduced in the 703 
presence of several lead compounds. Data (means ± SEM) are representative of three 704 
independent biological experiments. (b) Selected lead compounds were tested against A549, 705 
DU145, and HeLa cell lines. Data represents four independent biological replicates and all 706 
datapoints are normalized to Triton X-100 as above. A one-way ANOVA was performed with 707 
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Bonferroni corrective testing on all datasets and comparison relative to MeOH control is 708 
presented; * p ≤ 0.05, and *** p ≤ 0.001. 709 
 710 
Figure 6. Influence of HHQ analogues on PQS-dependent virulence phenotypes in P. 711 
aeruginosa. (a) Phenazine production and (b) pqsA-lacZ promoter activity quantified in a PAO1 712 
pqsA mutant in the presence of HHQ, PQS and lead compounds. Data is presented as mean +/- 713 
SEM and is representative of at least three independent biological replicates. A one-way 714 
ANOVA was performed with Bonferroni corrective testing and statistical significance relative to 715 
the MeOH control is presented; ** p ≤ 0.01 and *** p ≤ 0.001. 716 
 717 






